November 15, 2019 News by Grace Frank CHMP Favors Mayzent as Oral Treatment Specifically for Active SPMS Patients in EU The Committee for Medicinal Products for Human Use (CHMP) issued an opinion supporting MayzentĀ (siponimod) as an oral treatment specifically for adults with active secondary progressive multiple sclerosisĀ (SPMS) in the European Union. Opinions released by CHMP, an arm of the European Medicines Agency (EMA), carry weight and are…